Skip to main content

ADXS

Stock

ADXS

Stock

Performance overview

ADXS Price
Price Chart

Forward-looking statistics

Beta
0.36
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

Sector
Industry
Website
Employees
Market cap

Fundamentals

Enterprise value$8.6M
Revenue$13.0K
Revenue per employee
Profit margin0.00%
Debt to equity-0.34

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$7.99
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$50
Avg trading volume (10 day)$43
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio-0.16
Price to sales394.16
P/E Ratio-0.16
Enterprise Value to Revenue658.31
Price to book

Upcoming events

Next earnings daySeptember 10, 2021
Next dividend day
Ex. dividend day

News

Advaxis Kick Starts Early-Stage Study For Prostate Cancer Immunotherapy

Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer.  The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.

Benzinga (July 15, 2021)
Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

Zacks Investment Research (April 18, 2019)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free